A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive
performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).